All News

My first introductions to medically relevant biology and chemistry began when I worked with Harvard professor Greg Verdine to figure out how enzymes recognized and repaired damaged DNA.

I started my career as a medical liaison. It was a wonderful opportunity to shape how companies and physicians further scientific understanding of difficult medical problems, focus on key research questions, and address unmet patient needs.

June Supplement TOC

I have had the tremendous good fortune of strong leadership throughout my career.

1 June 2009

I joined Merck in 1996 as a customer account representative, processing pharmaceutical and vaccine orders for our direct customers.

Prior to joining Exelixis, I was an investment banker at Goldman Sachs, focusing on M&A and corporate finance.

It's hard to believe that Michelle Dipp has been in the industry for only five years considering her significant impact thus far on it.

FDA slaps down Cheerios and forces pharma companies that use Google to make technical changes no consumer will ever notice. Big whoop.

Even in our crowd of underage overachievers, Luca Santarelli, MD, PhD, is a standout.

There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.

People define "work" differently. For some, it's making useful objects that you can see and touch.

I began my career with an interest in medicine and pharmaceutical sciences.

The Primary Care Business Unit at Pfizer has taken some major steps to respond to the needs of our customers.

I started out as a cardiovascular primary care sales rep with Merck in the UK.

At 22, Stephanie Bova left the United States to teach English in Japan.

I trained as a journalist and worked at news organizations where all the reporters wanted to cover politics and crime.

In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.

28 May 2009

28 May 2009

1 June 2009

Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.

21 May 2009

Neil Darwent and Roger Cooper of GSK Biologicals talk to Pharm Exec Europe about the company's new, state-of-the-art approach to clinical trials in Africa.

US pharma CEO salaries are still dwarfing the earnings of their European counterparts, but, with the industry and the economy currently in crisis, Jacky Law asks how long this can continue.

You know those loud soundtracks and distracting visuals during the safety information in your TV ads? Critics have been complaining about them, and new draft guidance from FDA is calling them a "no-no."

Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.

Defining, evaluating, and utilizing the Target Product Profile.